WR Hambrecht Upgrades Adolor to 'Buy'

Analyst Jason Kantor says Adolor gave positive results from a second Phase III trial for its postoperative intestinal blockage drug

WR Hambrecht upgraded drug maker Adolor (ADLR ) to buy from hold.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.